Literature DB >> 9236549

Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study.

S K Goldsmith1, R M Shapiro, J N Joyce.   

Abstract

BACKGROUND: Anatomical substrates for the clinical efficacy of D2 dopamine receptor antagonism in ameliorating positive symptoms, including auditory hallucinations, in schizophrenia are not fully known. We previously identified a modular organization of D2 receptors unique to the temporal lobe. The dense bands of D2 receptors showed highest frequency in auditory and speech association cortices (Brodmann areas 22, 39, and 42) and auditory-visual association areas (Brodmann areas 20 and 37) but were rarely found in somatosensory association regions (Brodmann area 21). Since the anatomical localization of these bands mirrors the presumed sites underlying hallucinations in schizophrenia, the modular and laminar distribution of D2 receptors was studied in the temporal cortex in the brains of schizophrenic and control subjects.
METHODS: Tissue obtained post mortem from 12 elderly schizophrenic subjects and 13 controls matched for age and postmortem interval was examined by quantitative receptor autoradiography for D2 receptor binding with [125I]epidepride. All regions of the temporal lobe were sampled in all cases.
RESULTS: Schizophrenia cases exhibited significantly disrupted patterns of D2 receptors in the perirhinal, superior, and inferior temporal cortices, including disrupted patterns in the modular D2 receptor bands. The schizophrenic cases had reduced concentrations of D2 receptors in the supragranular layers and elevated concentrations of D2 receptors in the granular layer in isocortical regions of the temporal lobe. This disruption does not appear to be due to long-term treatment of antipsychotic drugs and is regionally specific as there were no differences between groups for concentrations or patterns of expression in the hippocampal complex.
CONCLUSIONS: Blockade of the disrupted distribution of D2 receptors in auditory and auditory-visual association cortices is a likely mechanism for the clinical efficacy of D2 antagonists in reducing hallucinations. The regionally specific, aberrant pattern of D2 receptors may be a symptom of anomalous cortical development in these regions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236549     DOI: 10.1001/archpsyc.1997.01830190077008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

1.  Midbrain dopamine D2/3 receptor binding in schizophrenia.

Authors:  Heli Tuppurainen; Jyrki T Kuikka; Mikko P Laakso; Heimo Viinamäki; Minna Husso; Jari Tiihonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

2.  MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant.

Authors:  Sandra Shi; Catherine Leites; Deli He; Daniel Schwartz; Winton Moy; Jianxin Shi; Jubao Duan
Journal:  J Biol Chem       Date:  2014-03-27       Impact factor: 5.157

3.  Dcc haploinsufficiency regulates dopamine receptor expression across postnatal lifespan.

Authors:  Matthew Pokinko; Alanna Grant; Florence Shahabi; Yvan Dumont; Colleen Manitt; Cecilia Flores
Journal:  Neuroscience       Date:  2017-01-17       Impact factor: 3.590

4.  18F-fallypride binding potential in patients with schizophrenia compared to healthy controls.

Authors:  Douglas S Lehrer; Bradley T Christian; Cemil Kirbas; Meicheng Chiang; Shawn Sidhu; Holly Short; Binquan Wang; Bingzhi Shi; King-Wai Chu; Brian Merrill; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2010-07-23       Impact factor: 4.939

5.  Parvalbumin neurons in the entorhinal cortex of subjects diagnosed with bipolar disorder or schizophrenia.

Authors:  Harry Pantazopoulos; Nicholas Lange; Ross J Baldessarini; Sabina Berretta
Journal:  Biol Psychiatry       Date:  2006-09-01       Impact factor: 13.382

6.  Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder.

Authors:  E R Bychkov; M R Ahmed; V V Gurevich; J L Benovic; E V Gurevich
Journal:  Neurobiol Dis       Date:  2011-07-20       Impact factor: 5.996

7.  Autophagy and Schizophrenia: A Closer Look at How Dysregulation of Neuronal Cell Homeostasis Influences the Pathogenesis of Schizophrenia.

Authors:  Jaime L Schneider; Ann M Miller; Mary E Woesner
Journal:  Einstein J Biol Med       Date:  2016

8.  Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression.

Authors:  Leisa A Glantz; John H Gilmore; David H Overstreet; Kayvon Salimi; Jeffrey A Lieberman; L Fredrik Jarskog
Journal:  Schizophr Res       Date:  2010-01-13       Impact factor: 4.939

Review 9.  Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?

Authors:  Steven R Laviolette
Journal:  Schizophr Bull       Date:  2007-05-22       Impact factor: 9.306

Review 10.  Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes.

Authors:  Heike Tost; Tajvar Alam; Andreas Meyer-Lindenberg
Journal:  Neurosci Biobehav Rev       Date:  2009-06-24       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.